Abstract: A pharmaceutical delivery system for oral inhalation is disclosed through nebulization consisting of an inert supporting material impregnated with or deposited with pharmaceutically active ingredient which must be solubilized or suspended in a pharmaceutical solvent to form a solution or suspension prior to administration. Each pharmaceutical delivery unit dosage form comprises one or more therapeutically effective and safe amounts of pharmaceutically active ingredient uniformly impregnated in or deposited on a supporting material which is a natural or synthetic polymer, woven or non-woven fabrics, inert paper, inorganic materials such as foil and combination thereof in a single or multi-layer lamination in a form of a sheet or strip or film or membrane or sponge-like or cup or well. The dosage form of this invention is to be administered to a patient through oral or nasal inhalation using a nebulizer after reconstitution with a reconstituting solvent.

Abstract: Compositions comprising both a sedative and a non-sedative antihistamine are disclosed as well as methods of inhibiting the release of histamines by administration of the compositions to a mammalian subject.

Abstract: A kit to alleviate tobacco-smoking withdrawal symptoms in a patient is disclosed which comprises: (a) a therapeutically effective amount of nicotine, at least one active nicotine metabolite, a combination of nicotine and an active nicotine metabolite, or an azapirone, or a pharmaceutically acceptable salt thereof; (b) a transdermal delivery system consisting essentially of a bupropion base in a therapeutically effective amount; and (c) a packaging material surrounding (a) and (b).

Abstract: A kit to alleviate tobacco-smoking withdrawal symptoms in a patient is disclosed which comprises:

Abstract: New pharmaceutical compositions in unit dosage form are disclosed for both intraoral and oral administration to a patient, said unit dosage form configured to be placed intraorally of said patient, which comprises:

Abstract: Novel pharmaceutical dosage forms provide for pulsatile delivery of an antiarrhythmic agent that releases the drug in spaced apart “pulses.” The dosage forms are comprised of first, second and optional third dosage units, with each dosage unit having a different drug release profile. The dosage forms may comprise capsules housing compressed tablets or drug-containing beads, granules, or particles or may comprise a single tablet with the first, second and optional third dosage units incorporated therein, or a “coated core” dosage form. Methods of treatment using the pharmaceutical dosage forms are provided as well.